Abstract 17281: Deep Venous Thrombosis is Associated With Poor Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Study From National Inpatient Database
Background: Heart failure with reduced ejection fraction is a major and independent risk factor of venous thromboembolism (VTE). However, very little is known about the association between VTE and Heart Failure with Preserved Ejection Fraction (HFpEF). We examined the prevalence and effects of acute VTE in patients hospitalized with HFpEF.
Methods: We performed a cross-sectional analysis using data collected from the Nationwide Inpatient Sample, 2013. ICD-9 codes were used to identify patients with HFpEF (ICD-9: 428.3), DVT (453.40-42, 453.82-89) and PE (415.1). Our primary outcomes were odds of acute VTE and its effects on inpatient mortality and length of stay. We used multivariable logistic regression to determine risk factors that affect mortality and linear regression to evaluate the effects of acute VTE on predicted length of stay (LOS). Data is presented as odds ratio (OR) with 95% confidence interval (CI) for categorical variables and mean difference (MD) with standard error (SEM) for continuous variables.
Results: An analysis of nearly 6 million hospitalizations identified 1.26 million patients with HFpEF. Patients with HFpEF had increased odds of acute VTE compared to the hospitalized patients without HFpEF [OR, 1.4; 95% CI (1.36 - 1.43), p <0.0001]. Inpatient mortality was higher [adjusted OR, 2.0; 95% CI (1.6 - 2.5)] and predicted LOS was longer (9.1± 0.23 days; p < 0.001) in patients with HFpEF and acute VTE compared with those without acute VTE. The length of stay was 6.4± 0.03 days in patients without VTE and 16.1± 0.43 days in those with acute VTE.
Conclusions: HFpEF is associated with an increased risk of acute VTE in hospitalized patients. The presence of acute VTE is associated with greater mortality and LOS in hospitalized patients with HFpEF. This highlights the importance of prophylactic anticoagulation in patients hospitalized with HFpEF.
Author Disclosures: V. Anand: None. S. Garg: None. S. Bano: None. R. Koene: None. T. Thenappan: None.
- © 2016 by American Heart Association, Inc.